Welcome to the
European Biotechnology Network!
The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe. The network, which kicked off in early 2009, is run by the European Biotechnology Foundation, a non-profit organisation based in Brussels.
Catch of the day:
Addex reports on new Alzheimer compound
03.09.2010 - Geneva - Allosteric modulation specialist Addex Pharmaceuticals Ltd has observed efficacy of its oral pre-clincal drug candidate mGluR2 NAM in a model of Alzheimer's disease. The allosteric compound specifically inhibits metabotropic glutamate receptor 2 (mGluR2). An Addex mGluR2 NAM is scheduled to enter Phase I clinical testing in healthy volunteers during 2011. In a model that mimics progressive memory impairment, observed in human Alzheimer's disease, mGluR2 NAM dose-dependently reversed memory deficit exhibited after beta-amyloid administration. Working memory impairment was measured using the so–called novel object recognition (NOR) test. The statistically significant effect was similar to the active comparator used in the same experiment, donepezil (Aricept), the benchmark marketed drug currently used to treat symptoms of Alzheimer's disease. Furthermore, the mGluR2 NAM did not change locomotor activity compared to vehicle.more news >>>